Sandgaard reiterated confidence in the NiCO pulse oximeter, with FDA approval anticipated within six months of submission. He projected commercialization and revenue generation to begin in 2026. Q1 ...

Q1 2025 Earnings Conference Call April 29, 2025 4:15 PM ETCompany ParticipantsBrian Prenoveau - IRThomas Sandgaard - ...

Philadelphia, Pennsylvania-- (Newsfile Corp. - April 28, 2025) - Berger Montague PC advises investors that a securities class action lawsuit has been filed against Zynex, Inc. ("Zynex" or the "Company ...

April 24, 2025) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a shareholder and consumer rights litigation firm, alerts investors that a securities class action lawsuit has been filed in the ...

Levi & Korsinsky, LLP notifies investors in Zynex, Inc. ("Zynex, Inc." or the "Company") of a class action securities lawsuit.

On April 15, 2025, RBC Capital Markets reportedly further reduced its price target for Zynex stock to $5 per share. This marks the second downward revision in as many months and represents a ...

Zynex further revealed "Tricare [health insurance program for the U.S. military] has temporarily suspended payments as they review prior claims." A lead plaintiff is a representative party who ...

Singh reportedly noted that Tricare, Zynex's largest customer, has temporarily suspended payments amid an ongoing review of prior claims. Singh added that the company's decision to withhold 2025 ...

Zynex further revealed “Tricare has temporarily suspended payments as they review prior claims.” Tricare is the health insurance program for the U.S. military. On this news, Zynex’s stock ...